Last reviewed · How we verify
NCT05053230: IMPROVE
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
NA trial testing IM@Home in Head and Neck Cancer in 480 participants. Currently enrolling.
20 September 2026
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 480 |
| Start date | 20 September 2021 |
| Primary completion | 20 September 2026 |
| Estimated completion | 20 September 2026 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- IM@Home
- Enhanced usual care
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Head and Neck Tumor — all drugs for Head and Neck Tumor →
- Thoracic Tumor — all drugs for Thoracic Tumor →
- Thoracic Cancer — all drugs for Thoracic Cancer →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Head and Neck Cancer or Head and Neck Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment.
Mao JJ, Bryl K, Gillespie EF, Green A, et al · · 2025 · cited 10× · PMID 39809874 · DOI 10.1038/s41746-024-01387-z -
Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment.
Verdini NP, Bryl KL, Baser RE, Lapen K, et al · · 2024 · cited 4× · PMID 38602690 · DOI 10.1001/jamaoncol.2024.0280 -
Reducing the Rate of Treatment Disruptions Through a Digital Structured Exercise and Mind-Body Program During Systemic Cancer Therapy: A Secondary Analysis of a Randomized Clinical Trial.
Bryl KL, Santos Teles M, Baser RE, Mao JJ, et al · · 2026 · PMID 41899585 · DOI 10.3390/cancers18060984 -
Benefits and Challenges of a Digital Exercise and Mind-Body Program During Active Cancer Treatment: Qualitative Study of Patients' Perceptions.
Bryl KL, Silverwood S, Desai K, Schobert K, et al · · 2026 · PMID 41543884 · DOI 10.2196/80075 -
A Virtual Mind-Body Exercise Program During Breast Radiation: Results From a Randomized Controlled Basket Trial.
Gillespie EF, Silverwood S, Lapen K, Verdini NP, et al · · 2026 · PMID 41202991 · DOI 10.1016/j.ijrobp.2025.10.036
Verify or expand the search:
- PubMed search for NCT05053230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05053230 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 9 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05053230.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing